Search terms
Results 11 - 20 of 92 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 10

Better treatment options for preventing cardiovascular disease are needed, particularly in very high risk patients such as those with diabetic complications. “The correlation between lower ...

Date : 29/08/2017

“Contrary to what has been believed for decades,” says Dr. Mente, “the Prospective Urban Rural Epidemiology (PURE) study revealed that a high-carbohydrate diet increases the risk of ...

Date : 29/08/2018

Double blind controlled trials have shown that CoQ10 improves symptoms, functional capacity and quality of life in patients with heart failure with no side effects. The primary endpoint was time to ...

Date : 25/05/2013

Paris, France, 28 August: The echocardiographic response (reduction of left ventricular end-systolic volume) evaluated at 6 months follow-up, demonstrated to be a better predictor of long-term ...

Date : 28/08/2011

Low BMI is a risk factor for CVD in hypertensive patients with diabetes, according to research presented at the ESC Congress today by Dr Takanori Nagahiro from Japan. Dr Nagahiro said: ...

Date : 03/09/2013

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous ...

Date : 17/05/2016

(1) The off-label use of the drug led to worse clinical outcomes including a doubled risk of hospitalisation compared to placebo. “Valvular disease is considered the next cardiac epidemic ...

Date : 28/08/2017

Findings from the PARADIGM-HF trial, published simultaneously in the New England Journal of Medicine, ? are extraordinarily powerful and compelling; they are destined to change the management of ...

Date : 30/08/2014

EMBARGO : 31 August 2015 at 09:00 BST The Hot Line results, presented at ESC Congress 2015 today, and published simultaneously in the European Journal of Preventive Cardiology, are the first evidence ...

Date : 31/08/2015

In the Hokusai VTE Cancer[1], cancer patients with (n=1050) were randomly assigned to either LMWH (at least 5 days) followed by the DOAC edoxaban (60 mg o.i.d.) or subcutaneous daltaparin (200 IU per ...

Date : 30/11/2018